Program Objectives

- Understand changes in state regulations: prohibition of use vs. use without dosing guidelines
- Understand Principles for Prescribing Oral Opioids (Workers’ Comp Guidelines – 2000)
- Understand magnitude of opioid-related complications
- Review of literature and data studies
- How to obtain and apply Agency Medical Director’s Opioid Dosing Guideline
Evidence-based & Coordinated Coverage Decisions

- SB 6088 establishes an Evidence-based Prescription Drug Program (2003):
  - A Pharmacy & Therapeutics (P&T) Committee
  - A Preferred Drug List (PDL)
  - An Endorsing Practitioner & Therapeutic Interchange Program (TIP)

- SHB 2575 establishes a Health Technology Assessment Program (2006):
  - A Health Technology Clinical Committee
  - Coverage policy/guideline for use

L&I’s Outpatient Drug Formulary

- A list of covered drugs commonly used to treat industrial injuries & occupational diseases

- Formulary is comprised of the PDL, department’s drug policies & pharmacy benefit management company

- Formulary decisions are primarily based on FDA-approved indications
Preferred Drug List

- Currently, the statewide PDL contains 26 drug classes
- Only a subset of the statewide PDL pertains to worker's compensation benefit
  - [http://www.lni.wa.gov/ClaimsIns/Providers/Treatment/Presc/PDL.asp](http://www.lni.wa.gov/ClaimsIns/Providers/Treatment/Presc/PDL.asp)

Evidence-based Clinical Guidelines

- Antiepileptic Drugs Guideline for Chronic Pain (PB 05-10)
RECENT Provider Bulletins

Provider Bulletins are temporary communications to announce changes to rules, law, policies and coverage decisions.

http://www.lni.wa.gov/ClaimsIns/Providers/Billing/ProvBulletins

<table>
<thead>
<tr>
<th>Subject</th>
<th>PB #</th>
<th>Covered?</th>
<th>Issue Date Year/Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home Modification Benefit</td>
<td>PB 07-09</td>
<td>With limitations</td>
<td>2007/10</td>
</tr>
<tr>
<td>Insurer Activity Prescription Form (APF)</td>
<td>PB 07-08</td>
<td>With limitations</td>
<td>2007/09</td>
</tr>
<tr>
<td>Hearing Aids, Replacement of Linear Analog</td>
<td>PB 07-07</td>
<td>Yes</td>
<td>2007/08</td>
</tr>
<tr>
<td>Brevio Nerve Conduction Testing System</td>
<td>PB 07-06</td>
<td>No</td>
<td>2007/07</td>
</tr>
<tr>
<td>Physical and Occupational Therapy Utilization Review</td>
<td>PB 07-04</td>
<td>With limitations</td>
<td>2007/06</td>
</tr>
<tr>
<td>Out-of-State Care Coordination Pilot Project</td>
<td>PB 07-05</td>
<td>With limitations</td>
<td>2007/06</td>
</tr>
<tr>
<td>X-STOP Implantable Interspinous Process Device</td>
<td>PB 07-03</td>
<td>No</td>
<td>2007/04</td>
</tr>
<tr>
<td>Pharmacy Incentive Payment Program</td>
<td>PB 07-01</td>
<td>N/A</td>
<td>2007/02</td>
</tr>
<tr>
<td>Pharmacy Billing, Third Party</td>
<td>PB 07-02</td>
<td>N/A</td>
<td>2007/02</td>
</tr>
</tbody>
</table>
Antiepileptic Drugs Guideline for Chronic Pain

- Collaboration with DSHS HRSA (Medicaid)
- Evidence-based report comparing newer to older antiepileptic drugs (AEDs) for treatment of neuropathic pain
- Inconsistent or no evidence to support newer AEDs except gabapentin as first-line agent for neuropathic pain

Antiepileptic Drugs Guideline for Chronic Pain

- No evidence to demonstrate AEDs significantly reduce acute pain, myofascial pain, low back pain, or other sources of somatic pain
- Newest AED (Lyrica) has been included in the update report
- Agencies will update this guideline to include the new information & coverage criteria in 2007
EDUCATIONAL PILOT PROJECT

Gary M. Franklin, MD, MPH

Medical Director
Department of Labor & Industries

Chairman,
Agency Medical Directors’ Group
(Washington State)

Research Professor
UW Departments of Environmental & Occupational Health Sciences and Neurology